Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry
Open Access
- 25 April 2022
- journal article
- research article
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 9 (4) , 1031-1047
Abstract
Rheumatic diseases are extensively managed with biological disease-modifying antirheumatic drugs (bDMARDs), but a notable proportion of patients withdraw in the long term because of lack of effectiveness, adverse events, or the patient’s decision. The present real-world analysis showed the effectiveness, retention, and safety data collected in the Spanish BIOBADASER registry for patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA, including ankylosing spondylitis (AS) and non-radiographic axSpA) treated with secukinumab, a human antibody against interleukin-17A (IL-17A), for more than 12 months. Six hundred and thirty-nine patients were analysed (350, 262, and 27 PsA, AS, and nr-axSpA patients, respectively). The results showed an improvement in the disease activity after 1 year of treatment, in terms of decreases of the mean Disease Activity Score 28 using C-reactive protein (DAS28-CRP), the mean Disease Activity Psoriatic Arthritis (DAPSA) score, swollen joint counts (SJC), and tender joint counts (TJC) in PsA patients and decreases in the mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the mean Ankylosing Spondylitis Disease Activity Score (ASDAS) in axSpA patients. This improvement was maintained or increased after 2 and 3 years of treatment, indicating that secukinumab is effective in both naïve and non-responder patients. Retention rates were higher when secukinumab was used as the first-line biological treatment, although they were also adequate in the second and third lines of treatment. Collected safety data were consistent with previous reports.Keywords
This publication has 47 references indexed in Scilit:
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 TrialsNew England Journal of Medicine, 2014
- Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD studyAnnals of the Rheumatic Diseases, 2013
- Clinical Response, Drug Survival, and Predictors Thereof Among 548 Patients With Psoriatic Arthritis Who Switched Tumor Necrosis Factor α Inhibitor Therapy: Results from the Danish Nationwide DANBIO RegistryArthritis & Rheumatism, 2013
- Increased risk of infectious disease requiring hospitalization among patients with psoriasis: A population-based cohortJournal of the American Academy of Dermatology, 2011
- Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scoresAnnals of the Rheumatic Diseases, 2011
- Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritisAnnals of the Rheumatic Diseases, 2010
- Responses to Adalimumab in Patients with Active Psoriatic Arthritis Who Have Not Adequately Responded to Prior Therapy: Effectiveness and Safety Results From an Open-label StudyThe Journal of Rheumatology, 2010
- The Disease Activity Score and the EULAR Response CriteriaRheumatic Disease Clinics of North America, 2009
- Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experienceAnnals of the Rheumatic Diseases, 2008
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995